Revance Therapeutics reported $1.57M in Interest Expense on Debt for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
Adamas Pharmaceuticals ADMS:US 3.5M 28K
Aerie Pharmaceuticals AERI:US $ 7.36M 0.24M
ALKERMES ALKS:US 2.44M 30K
Bristol Myers Squibb BMY:US $ 328M 2M
Coherus Biosciences CHRS:US $ 5.77M 0.02M
Eli Lilly And LLY:US $ 83.6M 3.3M
Endo International Ordinary Shares ENDP:US $ 142.99M 1.35M
Flexion Therapeutics FLXN:US $ 6.29M 1.11M
Gw Pharmaceuticals GWPH:US $ 0.29M 0.02M
JAZZ PHA JAZZ:US $ 93.47M 23.65M
Neurocrine Biosciences NBIX:US $ 6.6M 0.4M
Pacira Pharmaceuticals PCRX:US $ 7.33M 0.31M
Procter & Gamble PG:US $ 109M 8M
Revance Therapeutics RVNC:US $ 1.57M 2K
Supernus Pharmaceuticals SUPN:US $ 5.92M 1.43M
Teva Pharmaceutical Industries TEVA:US $ 232M 8M
Zogenix ZGNX:US $ 3.85M 0.06M